ADPT - Adaptive Biotechnologies Corp Stock Price, Fair Value and News

2.34USD-0.10 (-4.10%)Market Closed

Market Summary

USD2.34-0.10

Market Closed

-4.10%

ADPT Stock Price

View Fullscreen

ADPT RSI Chart

ADPT Valuation

Market Cap

339.5M

Price/Earnings (Trailing)

-1.51

Price/Sales (Trailing)

1.99

Price/Free Cashflow

-2.03

ADPT Price/Sales (Trailing)

ADPT Profitability

Return on Equity

-73.04%

Return on Assets

-34.07%

Free Cashflow Yield

-49.19%

ADPT Fundamentals

ADPT Revenue

Revenue (TTM)

170.3M

Rev. Growth (Yr)

-17.05%

Rev. Growth (Qtr)

20.74%

ADPT Earnings

Earnings (TTM)

-225.3M

Earnings Growth (Yr)

-73.05%

Earnings Growth (Qtr)

-38.05%

Breaking Down ADPT Revenue

Last 7 days

-10.7%

Last 30 days

-28.4%

Last 90 days

-43.2%

Trailing 12 Months

-72.4%

How does ADPT drawdown profile look like?

ADPT Financial Health

Current Ratio

4.66

Debt/Equity

0.42

Debt/Cashflow

-1.2

ADPT Investor Care

Shares Dilution (1Y)

1.30%

Diluted EPS (TTM)

-1.56

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	184.3M	189.6M	179.7M	170.3M
2022	154.5M	159.7M	168.0M	185.3M
2021	115.9M	133.4M	146.6M	154.3M
2020	93.3M	92.2M	92.4M	98.4M
2019	58.6M	69.2M	78.1M	85.1M
2018	0	44.2M	49.9M	55.7M
2017	0	0	0	38.4M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Adaptive Biotechnologies Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 12, 2024	neupert peter m	acquired	12,600	0.84	15,000	-
Mar 05, 2024	peterson tycho	sold	-53,168	3.44	-15,456	chief financial officer
Mar 05, 2024	taylor stacy l	sold	-45,962	3.43494	-13,381	svp and general counsel
Mar 05, 2024	lo francis	sold	-50,439	3.43123	-14,700	chief people officer
Mar 05, 2024	piskel kyle	sold	-26,503	3.43	-7,727	principal accounting officer
Mar 05, 2024	rubinstein julie	sold	-135,764	3.47489	-39,070	president
Mar 05, 2024	bobulsky susan	sold	-44,628	3.43537	-12,991	chief commercial officer, mrd
Mar 05, 2024	robins chad m	sold	-167,007	3.43121	-48,673	ceo and chairman
Mar 05, 2024	benzeno sharon	sold	-100,994	3.43634	-29,390	chief commercial ofc imm med
Mar 04, 2024	lo francis	acquired	-	-	99,976	chief people officer

Which funds bought or sold ADPT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 16, 2024	TSFG, LLC	sold off	-100	-	-	-%
Apr 16, 2024	Pinnacle Bancorp, Inc.	unchanged	-	-1,305	2,478	-%
Apr 16, 2024	Asset Dedication, LLC	unchanged	-	-2,000	4,000	-%
Apr 16, 2024	CALTON & ASSOCIATES, INC.	sold off	-100	-116,529	-	-%
Apr 16, 2024	Rappaport Reiches Capital Management, LLC	unchanged	-	-115,055	218,537	0.07%
Apr 16, 2024	Bouvel Investment Partners, LLC	added	1.84	-73,723	147,755	0.06%
Apr 16, 2024	Edge Wealth Management LLC	unchanged	-	-152,100	288,900	0.06%
Apr 15, 2024	GoalVest Advisory LLC	unchanged	-	-1,403	2,664	-%
Apr 15, 2024	Legato Capital Management LLC	unchanged	-	-216,412	411,053	0.05%
Apr 12, 2024	Financial Synergies Wealth Advisors, Inc.	sold off	-100	-986	-	-%

Are Funds Buying or Selling ADPT?

Are funds buying ADPT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ADPT

No. of Funds

Unveiling Adaptive Biotechnologies Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	viking global investors lp	20.7%	29,993,708	SC 13G/A
Feb 13, 2024	vanguard group inc	8.82%	12,767,684	SC 13G/A
Jan 29, 2024	ark investment management llc	8.85%	12,806,513	SC 13G/A
Jan 26, 2024	blackrock inc.	7.9%	11,421,554	SC 13G
Feb 13, 2023	blackrock inc.	8.7%	12,374,197	SC 13G
Feb 10, 2023	ark investment management llc	6.43%	9,201,245	SC 13G
Feb 09, 2023	vanguard group inc	8.25%	11,794,168	SC 13G/A
Sep 12, 2022	price t rowe associates inc /md/	2.9%	4,081,518	SC 13G/A
Feb 14, 2022	matrix capital management company, lp	8.20%	11,572,590	SC 13G/A
Feb 14, 2022	viking global investors lp	21.3%	29,993,708	SC 13G/A

Recent SEC filings of Adaptive Biotechnologies Corp

View All Filings

Date Filed	Form Type	Document
Apr 09, 2024	8-K	Current Report
Apr 05, 2024	8-K	Current Report
Apr 02, 2024	8-K	Current Report
Mar 13, 2024	4	Insider Trading
Mar 06, 2024	4	Insider Trading
Mar 06, 2024	3	Insider Trading
Mar 06, 2024	4	Insider Trading
Mar 06, 2024	4	Insider Trading
Mar 06, 2024	4	Insider Trading
Mar 06, 2024	4	Insider Trading

Peers (Alternatives to Adaptive Biotechnologies Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.0B	6.8B	-2.93%	-28.56%	-8.27	5.69	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.3B	1.8B	-2.14%	-28.32%	-41.48	9.99	76.23%	61.08%
BMRN	17.0B	2.4B	5.64%	-9.07%	101.38	7.03	15.42%	18.43%
INCY	11.9B	3.7B	-9.46%	-28.45%	19.84	3.21	8.87%	75.42%
MID-CAP
APLS	5.7B	396.6M	-16.55%	-42.15%	-10.83	14.44	425.83%	18.94%
BBIO	4.4B	-	-12.14%	49.76%	-6.72	60.35	54.84%	-34.79%
AXSM	3.1B	270.6M	-14.48%	-8.88%	-13.02	11.51	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.72%	-14.74%	-45.89	3.87	40.45%	71.62%
ARWR	2.8B	240.7M	-18.65%	-25.84%	-9.43	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-6.41%	-11.48%	25.32	4.54	85.90%	-14.05%
NVAX	544.4M	983.7M	-21.26%	-56.58%	-1	0.55	-50.36%	17.16%
CRBP	382.8M	881.7K	-14.69%	262.26%	-8.58	466.16	-77.61%	-5.33%
INO	238.4M	4.9M	-4.49%	-3.41%	-1.76	48.98	-54.97%	51.71%
IBIO	6.2M	2.1M	67.92%	36.92%	-0.23	2.14	-13.45%	66.37%

Adaptive Biotechnologies Corp News

Latest updates

Adaptive Biotechnologies Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	20.7%	45,784,000	37,919,000	48,926,000	37,647,000	55,198,000	47,830,000	43,660,000	38,620,000	37,930,000	39,467,000	38,505,000	38,442,000	30,185,000	26,299,000	20,988,000	20,910,000	24,209,000	26,058,000	22,138,000	12,666,000	17,192,000
Costs and Expenses	31.5%	116,852,000	88,875,000	96,744,000	94,840,000	94,384,000	93,261,000	96,162,000	101,687,000	99,526,000	95,792,000	88,270,000	79,722,000	74,424,000	63,348,000	57,897,000	55,530,000	48,397,000	44,111,000	38,243,000	32,711,000	31,336,000
S&GA Expenses	6.9%	21,906,000	20,493,000	23,872,000	22,308,000	23,716,000	21,513,000	24,281,000	26,093,000	26,696,000	24,949,000	23,216,000	20,604,000	18,545,000	14,474,000	14,332,000	14,007,000	12,640,000	9,099,000	8,897,000	7,817,000	8,071,000
R&D Expenses	0.7%	28,746,000	28,533,000	32,237,000	32,601,000	31,222,000	35,658,000	37,037,000	37,839,000	34,699,000	36,072,000	37,800,000	33,772,000	35,831,000	30,314,000	25,992,000	23,935,000	21,189,000	20,506,000	16,527,000	12,483,000	11,067,000
EBITDA Margin	-	-	-	-	-	-	-	-1.19	-1.25	-1.26	-	-	-1.07	-1.26	-0.50	-0.50	-0.50	-0.54	-	-	-	-
Interest Expenses	-17.5%	3,012,000	3,652,000	3,605,000	3,531,000	-	653,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	688,000	-1,481,000	-323,000	-	-	-	-	-
EBT Margin	-	-	-	-	-	-	-	-1.30	-1.34	-1.34	-	-	-1.26	-1.49	-0.74	-0.74	-0.74	-0.81	-	-	-	-
Net Income	-38.1%	-69,441,000	-50,300,000	-47,810,000	-57,699,000	-40,128,000	-45,281,000	-52,046,000	-62,736,000	-58,084,500	-55,903,000	-55,998,000	-40,642,000	-44,570,000	-36,719,000	-33,535,000	-31,403,000	-20,611,000	-13,950,000	-15,659,000	-18,386,000	-13,271,000
Net Income Margin	-21.3%	-1.32	-1.09	-1.01	-1.06	-1.08	-1.30	-1.43	-1.51	-1.36	-1.34	-1.33	-1.34	-	-	-	-	-	-	-	-	-
Free Cashflow	42.9%	-28,230,000	-49,462,000	-27,253,000	-62,076,000	-32,561,000	-47,840,000	-52,363,000	-67,530,000	-63,071,000	-58,062,000	-59,254,000	-74,086,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-7.9%	661	718	765	791	857	884	807	858	923	993	1,033	1,072	1,116	1,095	855	875	912	917	601	467	333
Current Assets	-5.8%	410	435	477	501	562	564	439	419	403	467	644	765	727	877	600	585	613	601	442	-	181
Cash Equivalents	-26.7%	65.00	89.00	109	95.00	90.00	218	76.00	115	139	122	184	174	123	497	365	213	97.00	75.00	48.00	-	55.00
Inventory	-25.9%	14.00	19.00	19.00	20.00	14.00	17.00	19.00	21.00	19.00	18.00	19.00	17.00	14.00	11.00	11.00	11.00	9.00	9.00	8.00	-	8.00
Net PPE	-11.1%	68.00	77.00	79.00	81.00	83.00	87.00	87.00	86.00	85.00	88.00	75.00	56.00	40.00	31.00	27.00	25.00	60.00	47.00	22.00	-	19.00
Goodwill	0%	119	119	119	119	119	119	119	119	119	119	119	119	119	119	119	119	119	119	119	-	119
Liabilities	-0.9%	353	356	369	368	393	396	288	305	319	341	340	346	373	320	325	323	341	331	324	177	30.00
Current Liabilities	-5.7%	88.00	93.00	95.00	90.00	110	104	111	115	114	122	117	107	105	101	93.00	78.00	78.00	73.00	75.00	-	23.00
Long Term Debt	3.1%	131	127	-	-	125	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	3.1%	131	127	-	-	125	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-14.7%	308	362	396	424	464	488	518	553	604	652	693	726	743	775	530	552	571	586	-	-	-
Retained Earnings	-6.5%	-1,144	-1,074	-1,024	-976	-919	-878	-833	-781	-718	-657	-601	-552	-511	-467	-430	-396	-365	-344	-330	-	-295
Additional Paid-In Capital	1.1%	1,453	1,437	1,422	1,403	1,387	1,373	1,358	1,340	1,324	1,309	1,295	1,277	1,254	1,241	958	945	936	930	46.00	-	38.00
Shares Outstanding	0.2%	145	145	145	144	143	143	142	142	140	140	140	139	-	-	-	-	-	-	-	-	-
Minority Interest	-27.4%	-0.12	-0.09	-0.07	-0.07	-0.07	-0.03	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	756	-	-	-	899	-	-	-	3,951	-	-	-	3,590	-	-	-	2,009	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	42.3%	-26,932	-46,684	-23,556	-59,152	-30,019	-42,408	-47,065	-64,453	-53,826	-43,443	-37,213	-58,245	-39,844	-47,156	-31,077	-31,606	-26,791	-30,138	-15,970	278,303	-5,410
Share Based Compensation	1.4%	15,556	15,336	17,345	14,671	14,294	14,142	14,180	12,861	11,875	11,643	11,249	8,484	7,243	6,470	6,373	4,675	3,445	3,300	3,300	3,046	3,046
Cashflow From Investing	-87.7%	3,207	26,138	37,323	62,979	-97,544	58,015	4,746	37,688	67,212	-21,268	41,447	93,819	-340,049	-97,246	177,492	142,759	46,680	-260,852	-45,349	-222,176	27,629
Cashflow From Financing	411.8%	87.00	17.00	1,469	672	6.00	125,520	3,990	2,749	3,278	2,926	6,328	14,614	6,253	276,038	6,337	4,959	1,746	319,550	-1,504	124	278

ADPT Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue
Revenue	$ 170,276	$ 185,308	$ 154,344
Operating expenses
Cost of revenue	75,553	57,909	49,301
Research and development	122,117	141,756	142,343
Sales and marketing	88,579	95,603	95,465
General and administrative	83,934	88,527	74,502
Amortization of intangible assets	1,699	1,699	1,699
Impairment of right-of-use and related long-lived assets	25,429
Total operating expenses	397,311	385,494	363,310
Loss from operations	(227,035)	(200,186)	(208,966)
Interest and other income, net	15,531	4,056	1,668
Interest expense	(13,800)	(4,238)
Net loss	(225,304)	(200,368)	(207,298)
Add: Net loss attributable to noncontrolling interest	54	177	19
Net loss attributable to Adaptive Biotechnologies Corporation	$ (225,250)	$ (200,191)	$ (207,279)
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic	$ (1.56)	$ (1.4)	$ (1.48)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic	144,383,294	142,515,917	140,354,915
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted	$ (1.56)	$ (1.4)	$ (1.48)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted	144,383,294	142,515,917	140,354,915

ADPT Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 65,064	$ 90,030
Short-term marketable securities (amortized cost of $281,122 and $412,282, respectively)	281,337	408,166
Accounts receivable, net	37,969	40,057
Inventory	14,448	14,453
Prepaid expenses and other current assets	11,370	9,440
Total current assets	410,188	562,146
Long-term assets
Property and equipment, net	68,227	83,447
Operating lease right-of-use assets	52,096	80,763
Restricted cash	2,932	2,398
Intangible assets, net	5,128	6,827
Goodwill	118,972	118,972
Other assets	3,591	2,064
Total assets	661,134	856,617
Current liabilities
Accounts payable	7,719	8,084
Accrued liabilities	8,597	12,424
Accrued compensation and benefits	13,685	15,935
Current portion of operating lease liabilities	9,384	9,230
Current portion of deferred revenue	48,630	64,115
Total current liabilities	88,015	109,788
Long-term liabilities
Operating lease liabilities, less current portion	89,388	98,772
Deferred revenue, less current portion	44,793	58,599
Revenue interest liability, net	130,660	125,360
Total liabilities	352,856	392,519
Commitments and contingencies (Note 12)
Shareholders’ equity
Preferred stock: $0.0001 par value, 10,000,000 shares authorized at December 31, 2023 and 2022; no shares issued and outstanding at December 31, 2023 and 2022
Common stock: $0.0001 par value, 340,000,000 shares authorized at December 31, 2023 and 2022; 145,082,271 and 143,105,002 shares issued and outstanding at December 31, 2023 and 2022, respectively	14	14
Additional paid-in capital	1,452,502	1,387,349
Accumulated other comprehensive gain (loss)	215	(4,116)
Accumulated deficit	(1,144,332)	(919,082)
Total Adaptive Biotechnologies Corporation shareholders’ equity	308,399	464,165
Noncontrolling interest	(121)	(67)
Total shareholders’ equity	308,278	464,098
Total liabilities and shareholders’ equity	$ 661,134	$ 856,617

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer and autoimmune disorders. It offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

CEO	Mr. Chad M. Robins M.B.A, M.B.A.
WEBSITE	adaptivebiotech.com
INDUSTRY	Biotechnology
EMPLOYEES	790

Adaptive Biotechnologies Corp Frequently Asked Questions

What is the ticker symbol for Adaptive Biotechnologies Corp? What does ADPT stand for in stocks?

ADPT is the stock ticker symbol of Adaptive Biotechnologies Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Adaptive Biotechnologies Corp (ADPT)?

As of Thu Apr 18 2024, market cap of Adaptive Biotechnologies Corp is 339.52 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ADPT stock?

You can check ADPT's fair value in chart for subscribers.

What is the fair value of ADPT stock?

You can check ADPT's fair value in chart for subscribers. The fair value of Adaptive Biotechnologies Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Adaptive Biotechnologies Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ADPT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Adaptive Biotechnologies Corp a good stock to buy?

The fair value guage provides a quick view whether ADPT is over valued or under valued. Whether Adaptive Biotechnologies Corp is cheap or expensive depends on the assumptions which impact Adaptive Biotechnologies Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ADPT.

What is Adaptive Biotechnologies Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 18 2024, ADPT's PE ratio (Price to Earnings) is -1.51 and Price to Sales (PS) ratio is 1.99. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ADPT PE ratio will change depending on the future growth rate expectations of investors.